安进质量负责人Jackie Elbonne将于年底退休,内部继任者Aine Hanly明年接任首席质量官
Amgen's quality chief to retire as internal successor steps up
安进首席质量官Jackie Elbonne博士将于年底退休,其副手、现任质量副总裁Aine Hanly博士明年接任该职。Elbonne拥有横跨七家公司的35年生物制药经验,此前曾任百时美施贵宝首席质量官。Hanly于2012年加入安进,2021至2025年任Vir Biotechnology首席技术官,去年回到安进担任现职。

Aine Hanly, Ph.D., will become Amgen's new chief quality officer next year. (z_wei/iStock/Getty Images Plus)
Biopharma industry veteran Jackie Elbonne, Ph.D., is retiring at the end of the year, leaving Amgen’s top quality spot to her deputy Aine Hanley, Ph.D.
Elbonne brought 35 years of biopharma experience across seven companies to the Amgen’s C-suite. Prior to her current role, she was chief quality officer at Bristol Myers Squibb, where she led quality and compliance oversight across the company’s biologics, pharmaceutical and cell therapy portfolios worldwide. And before BMS she held senior leadership positions at Merck & Co.

“My journey began in the UK as a young organic chemistry Ph.D. graduate from the University of Liverpool and took me across continents, countless countries, and six mergers and acquisitions,” Elbonne wrote in a LinkedIn post announcing her forthcoming retirement. “Looking back, I’m proud to have contributed to scientific breakthroughs and medicines that have impacted millions of patients around the world—including members of my own family,” she said.
Stepping up to fill Elbonne’s shoes is her lieutenant and Amgen’s vice president of quality.
Hanly has more than a decade at both Pfizer and Amgen, the latter of which she joined in 2012. From 2021 to 2025, Hanley was the chief technology officer of Vir Biotechnology where she oversaw technical operations, manufacturing and supply chain, before returning to Amgen to take up her current role last year.
“Across those experiences, I’ve seen how a shared purpose brings people together around the patients we serve,” Hanly said in a LinkedIn post announcing her new position. “Quality is how we earn the trust patients place in our medicines, through the integrity of our data and the choices we make every day. At Amgen, that trust is central to our mission to serve patients.”
In her post, Hanley thanked Elbonne for all she’d contributed to Amgen and her support as they transition the CQO role.
Amgen did not respond to Fierce's request for comments.
Elbonne marks the third member of the Amgen C-suite to retire this year. Former CFO Peter Griffith retired in August, and former chief technology officer, David Reese, M.D. retired in June.
来源:Fierce Pharma Manufacturing · fiercepharma.com